Akari Therapeutics Showcases Promising ASCO Data on AKTX-101

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 3 days ago

0mins

AKTX-25.49%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

ASCO Data Highlight: Akari Therapeutics' first ASCO abstract acceptance showcases the synergy of AKTX-101 with a KRAS inhibitor in KRAS-mutated pancreatic cancer models, indicating its potential to transform treatment options for difficult-to-treat cancers.
Innovative Drug Platform: AKTX-101 employs a unique PH1 payload targeting the Trop2 receptor on cancer cells, demonstrating significant anti-tumor activity and prolonged survival, particularly in combination with checkpoint inhibitors, highlighting its synergistic effects.
Clinical Trial Plans: The company aims to initiate its first-in-human clinical trial for AKTX-101 by mid-2027, marking a critical milestone in its product development that is expected to attract investor interest and potentially drive stock price increases.
Broad Market Prospects: With the rising demand for treatments targeting KRAS-driven tumors, Akari's innovative drug platform is poised to capture a significant share in the rapidly evolving ADC market, addressing substantial unmet medical needs.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AKTX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on AKTX

Wall Street analysts forecast AKTX stock price to fall

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 22.050

Low

1.00

Averages

3.33

High

7.00

Current: 22.050

Low

1.00

Averages

3.33

High

7.00

Maxim

Buy -> Hold

downgrade

2026-04-09

Reason

Maxim

Price Target

AI Analysis

2026-04-09

downgrade

Buy -> Hold

Reason

Maxim downgraded Akari Therapeutics to Hold from Buy without a price target. The selloff post the partnership with WuXi XDC is due in part due to Akari's additional capital needs and continued pressure following the ratio change that took effect on March 31, the analyst tells investors in a research note. With the shares near an all-time low and a market capitalization below $5M, Maxim believes the company's risks are elevated in an already challenging financing environment. It cites funding risk for the downgrade.

Maxim

Jason McCarthy

Buy

Hold

downgrade

2026-04-08

Reason

Maxim

Jason McCarthy

Price Target

2026-04-08

downgrade

Buy

Hold

Reason

Maxim analyst Jason McCarthy downgraded Akari Therapeutics to Hold from Buy.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AKTX

Unlock Now

About AKTX

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm

2 days agoNASDAQ.COM

Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.

U.S. Stocks Reach Record Highs as Investor Optimism Grows

2 days agostocktwits

Strong Market Performance: The S&P 500 rose by 0.6%, the Nasdaq 100 increased by 0.6%, and the Dow Jones inched up by 0.1%, all hitting record highs, reflecting investor optimism about future economic recovery.
Consumer Spending Recovery: Adjusted for inflation, consumer spending increased by 0.1% in April after a 1.6% rise in March, indicating a gradual restoration of consumer confidence that could drive economic growth.
International Situation Impact: Market sentiment improved following news of a 60-day memorandum of understanding between U.S. and Iranian negotiators, leading to a pullback in oil prices to around $89 per barrel, highlighting investor concerns over geopolitical risks.
Strong ETF Performance: The SPDR S&P 500 ETF and Invesco QQQ Trust rose approximately 0.6% and 1% respectively, reflecting strong investor interest in tech and consumer stocks, further propelling the market upward.

Akari Therapeutics Shows Promising Cancer Treatment Progress

2 days agostocktwits

Promising Preclinical Data: CEO of Akari Therapeutics highlighted that the ADC platform showed encouraging results in pancreatic cancer models with KRAS mutations, indicating its potential to redefine treatment for difficult-to-treat KRAS-driven cancers, particularly where current options are limited.
Funding for Trials: The company announced a $5.5 million private financing deal to support the Phase 1 clinical trial of AKTX-101, which is set to begin by mid-2027, ensuring necessary funding for advancing its clinical research efforts.
Stock Surge: Following the CEO's remarks on the ADC platform's potential, Akari's shares surged nearly 50% on Thursday, reflecting strong market enthusiasm ahead of an upcoming oncology conference and investor confidence in the company's future prospects.
Bullish Market Sentiment: Retail sentiment on Stocktwits for AKTX remained in the 'extremely bullish' territory over the past 24 hours, with high message volumes indicating expectations of a potential buyout by big pharma, further fueling the stock's upward momentum.